Please provide your email address to receive an email when new articles are posted on . Even with algorithms available, dosing for Mircera appears to vary widely among nephrologists. Dialysis clinics ...

Roche announced today that the U.S. Food and Drug Administration (FDA) has approved Mircera (methoxy polyethylene glycol-epoetin beta) for the treatment of anaemia associated with chronic kidney ...

The approval was based on an open-label, multiple dose, multicenter, dose-finding study in 64 pediatric patients with CKD who were on hemodialysis and who had stable hemoglobin levels while previously ...

Roche announced that the FDA has approved Mircera (methoxy polyethylene glycol-epoetin beta) for the treatment of anemia associated with CKD in adults, including dialysis patients and patients not on ...

Roche announced today that the European Commission has approved its innovative drug Mircera to treat anaemia associated with chronic kidney disease (CKD). The approval of Mircera results in a single ...

ZURICH, April 13 (Reuters) - Swiss drugmaker Roche's experimental medicine Mircera is safe and effective for the treatment of renal anaemia associated with chronic kidney disease, pooled data from ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved Mircera for the treatment of pediatric patients 5 to 17 years of age on hemodialysis who are ...

BASEL, Switzerland, October 29 /PRNewswire/ -- A new study on pain published today has found that subcutaneous (SC) injections of the new renal anaemia therapy MIRCERA is associated with significantly ...